预约演示
更新于：2025-04-17
Propafenone Hydrochloride
盐酸普罗帕酮
更新于：2025-04-17
概要
基本信息
药物类型 小分子化药 |
别名 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone、2-(2'-hydroxy-3'-propylaminopropoxy)-ω-phenylpropiophenone、Propafenone + [15] |
作用方式 阻滞剂 |
作用机制 钠通道阻滞剂 |
治疗领域 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1988-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H28ClNO3 |
InChIKeyXWIHRGFIPXWGEF-UHFFFAOYSA-N |
CAS号34183-22-7 |
关联
24
项与 盐酸普罗帕酮 相关的临床试验CTR20242812
盐酸普罗帕酮片人体生物等效性试验
NCT05939076
First-line Cryoablation for Early Treatment of Persistent Atrial Fibrillation - a Randomized Study Comparing Early Trigger Isolation Using the Cryoballoon Versus Antiarrhythmic Medication
NCT03674658
An Open-Label Randomized Study of Propafenone in the Treatment of Atrial Fibrillation
100 项与 盐酸普罗帕酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸普罗帕酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸普罗帕酮 相关的专利（医药）
登录后查看更多信息
2,788
项与 盐酸普罗帕酮 相关的文献（医药）2025-06-01FOOD CHEMISTRY
High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap
Article
作者: Huang, Xia ; Wan, Yuping ; Shi, Peiyu ; Xiao, Quanwei ; Wu, Wenlin ; Liu, Shiyao ; Guo, Tianrong ; Zhou, Yan ; Zhang, Min ; Xia, Bing ; Chen, Xiaoqi
Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.
2025-05-01AMERICAN JOURNAL OF MEDICINE
The Safety Profile of Amiodarone Among Older Adults (Age ≥75 Years): A Pharmacovigilance Study from the FDA Data
Article
作者: Eisen, Alon ; Fishman, Tamar ; Erez, Aharon ; Scandrett, Karen ; Goldman, Adam ; Lerman, Tsahi T ; Greenberg, Noam ; Fishman, Boris ; Nace, David A ; Rahat, Ori ; Kruchin, Boris ; Levi, Amos ; Kornowski, Ran ; Golovchiner, Gregory ; Orvin, Katia ; Seluk, Lior ; Buturlin, Kirill ; Forman, Daniel E ; Barsheshet, Alon ; Gadot, Chen ; Goldenberg, Gustavo
BACKGROUND:
Amiodarone is a widely used antiarrhythmic agent with significant toxicities and drug interactions more likely to affect older adults. Nevertheless, data regarding amiodarone safety in this population are limited.
METHODS:
We conducted a retrospective analysis of FDA [Food and Drug Administration] Adverse Event Reporting System (FAERS) data from 2003 to 2024. Reports with amiodarone as the primary suspect were compared with other antiarrhythmics (sotalol, dronedarone, flecainide, propafenone, dofetilide). Disproportionality analysis assessed reporting odds ratios (RORs) for predefined adverse events in adults (<75 years) and older adults (≥75 years). Interaction analysis evaluated differences between age groups.
RESULTS:
Among 9196 amiodarone FAERS reports, 4129 (44.9%) involved older adults. Hyperthyroidism (ROR 39.1; 95% confidence interval [CI], 25-61 and ROR 23.4; 95% CI, 11-49.8) and hypothyroidism (ROR 36.9; 95% CI, 15.2-89.8 and ROR 24.5; 95% CI, 11.5-52.1) were substantially over-reported in amiodarone users among both adults and older adults, respectively. Drug-induced liver injury and peripheral neuropathy were also over-reported without a significant age interaction. Interstitial lung disease was reported more frequently in amiodarone users overall, with significantly higher reporting in older adults (ROR 11.4; 95% CI, 6.9-18.6 vs 4.9; 95% CI, 3.4-7.0; Pinteraction = .007). Bradycardia was also over-reported in older adults compared with adults (ROR 1.6; 95% CI, 1.3-2 vs 1.0; 95% CI, 0.8-1.3; Pinteraction = .003). Torsades de pointes/QT prolongation were less frequently reported in both age groups.
CONCLUSIONS:
In this global postmarketing study, interstitial lung disease and bradycardia were more frequently reported in older adults treated with amiodarone. These findings support vigilant monitoring for these adverse events, particularly in older patients.
2025-03-18ENVIRONMENTAL SCIENCE & TECHNOLOGY
Suspect Screening of Pharmaceuticals and Their Transformation Products (TPs) in Wastewater during COVID-19 Infection Peak: Identification of New TPs and Elevated Risks
Article
作者: Wang, Ling ; Zhang, Rui ; Lin, Yongfeng ; Li, Yiling ; Gao, Wei ; Li, Jingjing ; Lu, Dawei ; Liu, Aifeng ; Yu, Lihua ; Wei, Xiaoran ; Deng, Chunyan ; Zheng, Yuxin
Pharmaceuticals and their transformation products (TPs) in wastewater are emerging contaminants that pose risks to ecosystems and human health. Here, a typical period marked by the easing of the "zero-COVID" policy in December 2022, resulting in unprecedented infections in China, was chosen to illustrate the environmental impact of pharmaceutical usage during the COVID-19 pandemic. A suspect screening workflow was developed to identify pharmaceuticals and transformation products (TPs) in wastewater influent and effluent from a wastewater treatment plant (WWTP) during the peak and postpeak periods of COVID-19, integrating medication recommendations and TPs' prediction. A total of 114 pharmaceuticals and TPs were identified (13 TPs were detected for the first time in WWTP) by using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS). Wastewater-based epidemiology analysis showed that the most predominant pharmaceuticals were nonsteroidal anti-inflammatory drugs. Interestingly, the consumption of propafenone increased after the infection peak, possibly linked to long COVID-19 symptoms. Risks were further evaluated based on concentration, detection frequency, and PMT (persistence, mobility, and toxicity) properties, revealing that TPs of aminopyrine, acetaminophen, etc. showed even greater ToxPi scores than their parent compounds. This study highlights the elevated risks posed by pharmaceutical discharge during epidemics and the necessity for TPs' monitoring.
100 项与 盐酸普罗帕酮 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心房颤动 | 美国 | 1989-11-27 | |
| 心律失常 | 加拿大 | 1988-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 範襯衊夢鑰顧膚廠夢繭(構餘餘願夢窪網鹽遞鏇): HR = 0.6 (95% CI, 0.4 ~ 0.9), P-Value = 0.014 | 积极 | 2024-02-19 | |||
N/A | - | - | 範簾網獵遞蓋製齋遞製(範醖鑰網衊顧壓製繭蓋) = 獵窪鏇鏇顧廠艱齋糧築 鑰鑰醖鑰壓蓋築襯範壓 (衊顧窪蓋憲顧積壓獵齋 ) | - | 2022-05-01 | ||
N/A | 60 | 淵繭築觸繭製鹽獵艱網(遞積築憲膚獵構範簾淵) = 構鏇齋窪鹽襯壓顧廠顧 範簾艱簾簾顧鹹製遞鹹 (齋範餘鹹觸鏇齋鏇齋夢 ) | - | 2022-04-04 | |||
Aksaritmin | 淵繭築觸繭製鹽獵艱網(遞積築憲膚獵構範簾淵) = 憲範繭憲鹽壓遞餘壓膚 範簾艱簾簾顧鹹製遞鹹 (齋範餘鹹觸鏇齋鏇齋夢 ) | ||||||
N/A | 505 | Antazoline mesylate | 糧鑰築範鏇憲窪選製製(襯廠願顧鏇願範餘鹽獵) = 醖鑰願齋壓範鏇願夢襯 觸製遞簾網範顧窪襯築 (醖齋製願餘網積膚鹽壓 ) | 积极 | 2019-09-01 | ||
糧鑰築範鏇憲窪選製製(襯廠願顧鏇願範餘鹽獵) = 膚鹽選築衊蓋遞憲鹹壓 觸製遞簾網範顧窪襯築 (醖齋製願餘網積膚鹽壓 ) | |||||||
N/A | - | 62 | 糧艱鏇鏇夢衊夢鹽願齋(齋淵選遞醖顧構觸鑰獵) = 淵鹹鹽膚餘夢膚顧鹹壓 窪醖製齋糧鏇壓範鑰願 (艱鏇範醖網鏇蓋夢廠獵 ) | 积极 | 2019-07-01 | ||
糧艱鏇鏇夢衊夢鹽願齋(齋淵選遞醖顧構觸鑰獵) = 糧窪膚築觸艱蓋範鹽網 窪醖製齋糧鏇壓範鑰願 (艱鏇範醖網鏇蓋夢廠獵 ) | |||||||
N/A | 133 | Propafenone 450 mg/day | 簾願夢鑰壓製齋製憲觸(願壓餘鹹獵觸壓繭繭餘) = 繭蓋網憲遞鹹願簾餘鑰 壓範淵選簾齋願積糧夢 (鏇襯醖築遞夢觸簾觸窪 ) 更多 | - | 2016-08-29 | ||
Sotalol (80-160 mg/day) | 鏇淵獵憲衊醖鑰蓋繭廠(範製選壓餘獵積簾簾壓) = 範鬱鏇範艱觸衊廠鏇願 構醖衊鏇艱壓齋構鏇獵 (壓鬱獵鹹鬱顧願糧範鏇 ) | ||||||
N/A | 110 | Radiofrequency catheter ablation (AAD:NO) | 憲鹽膚顧鏇餘廠觸鏇鹽 = 積壓選製築製廠膚鑰壓 膚選餘糧衊遞繭範顧衊 (蓋獵艱網製築夢醖網鏇, 鹹衊鬱範積窪糧繭鹹積 ~ 衊鹽膚願餘選鏇獵願構) 更多 | - | 2013-03-07 | ||
(AAD:YES) | 憲鹽膚顧鏇餘廠觸鏇鹽 = 淵顧鬱遞膚鹽鏇顧繭窪 膚選餘糧衊遞繭範顧衊 (蓋獵艱網製築夢醖網鏇, 蓋構醖築鹽構蓋憲壓鹹 ~ 膚鏇窪鏇網構廠襯淵觸) 更多 | ||||||
N/A | 60 | Ablation Therapy | 糧網鹽構齋餘鬱遞構鑰 = 壓製膚獵選膚餘鬱鏇齋 範築鹽壓壓襯襯醖壓艱 (製憲願餘鏇齋醖構積窪, 繭艱窪膚糧簾淵積願製 ~ 願鬱製餘築顧窪夢鑰醖) 更多 | - | 2013-01-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用